Last week, German based clinical stage biopharmaceutical company aiming to transform treatment of mental condition using various psychedelic therapies Atai Life Sciences announced that it will be going public in United States capital markets, Nasdaq to be precise.
The company says that it’s aiming for a market valuation of $2.3 billion post the initial public offering. This information was extracted from the regulatory filing the company made with U.S Securities and Exchange Commission on June 11.
According to the documents, Atai Life Sciences is intending to sell about 14.3 million shares in the offering. The company will be selling its shares for between $13 and $15 a piece in the IPO.
Shares of the company will start trading in Nasdaq under the ticker symbol ‘ATAI’ once the regulator gives this IPO a green light.